Biostate

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Von Willebrand Disease

Conditions

Von Willebrand Disease

Trial Timeline

Oct 1, 2010 → Mar 1, 2014

NCT ID

NCT01224808

About Biostate

Biostate is a phase 3 stage product being developed by CSL for Von Willebrand Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01224808. Target conditions include Von Willebrand Disease.

What happened to similar drugs?

4 of 6 similar drugs in Von Willebrand Disease were approved

Approved (4) Terminated (0) Active (2)

🔄Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing AgentsRochePhase 3

✅Blood coagulation Factor VIII and vWF, humanCSLApproved

🔄BiostateCSLPhase 3

✅VoncentoCSLApproved

✅Alphanate SD/HTGrifolsApproved

✅plasma-derived FVIII/VWF concentrateGrifolsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01445197	Phase 3	Terminated	Dec 1, 2012	Dec 1, 2013	Hemophilia A
NCT01224808	Phase 3	Completed	Oct 1, 2010	Mar 1, 2014	Von Willebrand Disease
NCT01229007	Phase 3	Completed	Aug 1, 2010	Jul 1, 2014	Hemophilia A
NCT01213446	Phase 3	Completed	Aug 1, 2010	Aug 1, 2013	Von Willebrand Disease

Competing Products

14 competing products in Von Willebrand Disease

See all competitors

Product	Company	Stage	Hype Score
Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate	Roche	Pre-clinical	33
Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents	Roche	Phase 3	47
Neumega (Oprelvekin, Interleukin 11, IL-11)	Pfizer	Phase 2	27
Oprelvekin, Interleukin 11, IL-11	Pfizer	Phase 2	35
recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11	Pfizer	Phase 2	35
efanesoctocog alfa (BIVV001)	Sanofi	Phase 1	29
Voncento®	CSL	Pre-clinical	26
Blood coagulation Factor VIII and vWF, human	CSL	Approved	43
Biostate® + Biostate®	CSL	Phase 2/3	38
VWF/FVIII products	CSL	Pre-clinical	26
Biostate	CSL	Phase 3	40
Voncento	CSL	Approved	43
Alphanate SD/HT	Grifols	Approved	44
plasma-derived FVIII/VWF concentrate	Grifols	Approved	47